A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
- 1 February 2014
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (2) , 319-324
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Case Series of Dermatologic Events Associated With the Insulin-Like Growth Factor Receptor 1 Inhibitor CixutumumabJournal of Clinical Oncology, 2011
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabBritish Journal of Cancer, 2010
- IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockageJournal of Hepatology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin‐like growth factor receptor in vitro and in an orthotopic modelHepatology Research, 2007
- Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cellsBiochemical Pharmacology, 2006
- Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trialJournal of Hepatology, 2005
- In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate TumorsClinical Cancer Research, 2005
- Structure and function of the type 1 insulin-like growth factor receptorCellular and Molecular Life Sciences, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000